

SUTTER MARTIN P  
Form 4  
May 09, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SUTTER MARTIN P

2. Issuer Name and Ticker or Trading Symbol  
ABIOMED INC [ABMD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
22 CHERRY HILL DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
05/08/2018

Director  10% Owner  
 Officer (give title below)  Other (specify below)

DANVERS, MA 01923

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, \$0.01 par value	05/08/2018		M		25,000	A	\$ 13.91
Common Stock, \$0.01 par value	05/08/2018		S <sup>(19)</sup>		700	D	\$ 340.4704 <u>(6)</u>
Common Stock, \$0.01 par value	05/08/2018		S <sup>(19)</sup>		400 <sup>(19)</sup>	D	\$ 341.9964 <u>(7)</u>

Edgar Filing: SUTTER MARTIN P - Form 4

Common Stock, \$0.01 par value	05/08/2018	<u>S<sup>(19)</sup></u>	<u>2,757<sup>(19)</sup></u>	D	\$ <u>342.7947<sup>(8)</sup></u>	187,520	D
Common Stock, \$0.01 par value	05/08/2018	<u>S<sup>(19)</sup></u>	<u>3,950<sup>(19)</sup></u>	D	\$ <u>343.7712<sup>(9)</sup></u>	183,570	D
Common Stock, \$0.01 par value	05/08/2018	<u>S<sup>(19)</sup></u>	<u>1,400<sup>(19)</sup></u>	D	\$ <u>344.6914<sup>(10)</sup></u>	182,170	D
Common Stock, \$0.01 par value	05/08/2018	<u>S<sup>(19)</sup></u>	<u>400<sup>(19)</sup></u>	D	\$ <u>345.6375<sup>(11)</sup></u>	181,770	D
Common Stock, \$0.01 par value	05/08/2018	<u>S<sup>(19)</sup></u>	<u>283<sup>(19)</sup></u>	D	\$ <u>346.5441<sup>(12)</sup></u>	181,487	D
Common Stock, \$0.01 par value	05/08/2018	M	12,000	A	\$ 18.63	193,487	D
Common Stock, \$0.01 par value	05/08/2018	S	800	D	\$ <u>340.4175<sup>(13)</sup></u>	192,687	D
Common Stock, \$0.01 par value	05/08/2018	S	200	D	\$ 341.84	192,487	D
Common Stock, \$0.01 par value	05/08/2018	S	2,700	D	\$ <u>342.6655<sup>(14)</sup></u>	189,787	D
Common Stock, \$0.01 par value	05/08/2018	S	5,300	D	\$ <u>343.6635<sup>(15)</sup></u>	184,487	D
Common Stock, \$0.01 par value	05/08/2018	S	1,900	D	\$ <u>344.5458<sup>(16)</sup></u>	182,587	D
	05/08/2018	S	700	D		181,887	D

Edgar Filing: SUTTER MARTIN P - Form 4

Common Stock, \$0.01 par value					\$ 345.3786 <u>(17)</u>			
Common Stock, \$0.01 par value	05/08/2018	S	400	D	\$ 346.2625 <u>(18)</u>	181,487	D	
Common Stock, \$0.01 par value	05/08/2018	A <sup>(20)</sup>	<u>6,546</u> <u>(20)</u>	A	\$ 329.01	188,033	D	
Common Stock, \$0.01 par value	05/08/2018	D <sup>(20)</sup>	<u>201,818</u> <u>(20)</u>	D	\$ 329.01	745,000	I	By Essex Woodland Health Ventures, VI, LP <sup>(1)</sup>
Common Stock, \$0.01 par value						503,182	I	By Essex Woodlands Health Ventures Fund VII, LP <sup>(2)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock option (right to buy) <sup>(3)</sup>	\$ 13.91	05/08/2018		M	25,000	05/20/2009 <sup>(4)</sup> 05/20/2018	Common Stock 25,000

Stock Option (right to buy) <sup>(5)</sup>	\$ 18.63	05/08/2018	M	12,000	08/12/2009	08/13/2018	Common Stock	12,000
Stock Option (right to buy) <sup>(5)</sup>	\$ 7.67				08/11/2010	08/12/2019	Common Stock	12,000
Stock Option (right to buy) <sup>(5)</sup>	\$ 9.99				08/10/2011	08/11/2020	Common Stock	12,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SUTTER MARTIN P 22 CHERRY HILL DRIVE DANVERS, MA 01923		X		

## Signatures

/s/ Stephen C. McEvoy (by power of attorney) 05/09/2018

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are held by Essex Woodlands Health Ventures Fund VI, L.P. Mr. Sutter is a managing director of Essex Woodlands Health Ventures, the partnership that owns the reported securities. As a managing director Mr. Sutter shares voting and investment powers for Essex Woodlands Health Ventures Fund VI, L.P.. Mr. Sutter disclaims beneficial ownership of all such securities except to the extent of his pecuniary interest therein.
  - (2) These securities are held by Essex Woodlands Health Ventures Fund VII, L.P.. Mr. Sutter is a managing director of Essex Woodlands Health Ventures, the partnership that owns the reported securities. As a managing director Mr. Sutter shares voting and investment powers for Essex Woodlands Health Ventures Fund VII, L.P. Mr. Sutter disclaims beneficial ownership of all such securities except to the extent of his pecuniary interest therein.
  - (3) Grant to reporting person to buy shares of Common Stock under ABIOMED, Inc. 2000 Stock Incentive Plan.
  - (4) These options become exercisable in annual 20% increments commencing on the date set forth in Table II, Column 6.
  - (5) Grant to reporting person of option to buy shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
  - (6) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$340.3300 and \$340.5700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
  - (7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$341.8400 and \$342.2700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

## Edgar Filing: SUTTER MARTIN P - Form 4

(8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$342.3300 and \$343.2900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(9) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$343.3400 and \$344.1800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(10) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$344.3700 and \$345.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(11) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$345.3500 and \$345.7600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(12) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$346.4000 and \$346.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(13) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$340.0000 and \$340.5800. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(14) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$342.1700 and \$342.9700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(15) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$343.1500 and \$343.9900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(16) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$344.0000 and \$344.9900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(17) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$345.0000 and \$345.7700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(18) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$346.0000 and \$346.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(19) Transaction represents shares of common stock sold for the payment of the exercise price of stock options and withholding taxes associated with stock option exercise.

(20) Essex Woodlands Health Ventures VI LP made an in-kind distribution of 201,818 shares of Abiomed Stock, in which Mr. Sutter as a limited partner of Essex Woodlands Health Ventures VI LP received 6,546 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.